부산대학교 도서관

Sakellaropoulos, T; Vougas, K; Narang, S; Koinis, F; Kotsinas, A; Polyzos, A; Moss, TJ; Piha-Paul, S; Zhou, H; Kardala, E; Damianidou, E; Alexopoulos, LG; Aifantis, I; Townsend, PA; Panayiotidis, MI; Sfikakis, P; Bartek, J; Fitzgerald, RC; Thanos, D; Shaw, KRM; Petty, R; Tsirigos, A; Gorgoulis, VG

Cell reports. 29(11):3367

Johnson A; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Ng PK; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Kahle M; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Castillo J; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Amador B; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Wang Y; Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Zeng J; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Holla V; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Vu T; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Su F; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Kim SH; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Conway T; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Jiang X; Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Chen K; Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Shaw KRM; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Yap TA; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Rodon J; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Mills GB; Division of Oncological Sciences, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.; Meric-Bernstam F; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. fmeric@mdanderson.org.; Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. fmeric@mdanderson.org.

Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE

Foster KI; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Shaw KRM; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Jin J; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Westin SN; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Yap TA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Glassman DM; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Jazaeri AA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Rauh-Hain JA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Lee S; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Fellman BM; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Ju Z; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Liu Y; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Fleming ND; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Sood AK; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

El Hussein S; Department of Hematopathology, Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA. sel2@mdanderson.org.; Shaw KRM; Khalifa Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Houston, TX, USA.; Vega F; Department of Hematopathology, Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX, USA.

Publisher: Elsevier Inc Country of Publication: United States NLM ID: 8806605 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-0285 (Electronic) Linking ISSN: 08933952 NLM ISO Abbreviation: Mod Pathol Subsets: MEDLINE

Raghav K; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Loree JM; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Morris JS; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Overman MJ; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Yu R; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Meric-Bernstam F; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Menter D; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Korphaisarn K; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Kee B; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Muranyi A; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Singh S; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Routbort M; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Chen K; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Shaw KRM; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Katkhuda R; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Shanmugam K; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Maru D; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Fakih M; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.; Kopetz S; Kanwal Raghav, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, Krittiya Korphaisarn, Brian Kee, Mark Routbort, Ken Chen, Kenna R.M. Shaw, Riham Katkhuda, Dipen Maru, and Scott Kopetz, The University of Texas MD Anderson Cancer Center, Houston, TX; Andrea Muranyi, Shalini Singh, and Kandavel Shanmugam, Ventana Medical Systems, Tucson, AZ; and Marwan Fakih, City of Hope Comprehensive Cancer Center, Duarte, CA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: PubMed not MEDLINE; MEDLINE

Shaw KRM; Khalifa Bin Zayed Institute for Personalized Cancer Therapy and Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; email: krshaw@mdanderson.org.; Maitra A; Khalifa Bin Zayed Institute for Personalized Cancer Therapy and Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; email: krshaw@mdanderson.org.

Publisher: Annual Reviews Country of Publication: United States NLM ID: 100911346 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-293X (Electronic) Linking ISSN: 15278204 NLM ISO Abbreviation: Annu Rev Genomics Hum Genet Subsets: MEDLINE

Arango NP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Brusco L; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Shaw KRM; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Chen K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Eterovic AK; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Holla V; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Johnson A; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Litzenburger B; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Khotskaya YB; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Sanchez N; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Bailey A; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Zheng X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Horombe C; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Kopetz S; Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Farhangfar CJ; Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.; Routbort M; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Broaddus R; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Bernstam EV; School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.; Division of General Internal Medicine, Medical School, The University of Texas Health Science Center at Houston, TX, USA.; Mendelsohn J; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Mills GB; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Meric-Bernstam F; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE

Zheng S; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. zhengs3@uthscsa.edu jdegroot@mdanderson.org.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Epidemiology and Biostatistics, Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas.; Alfaro-Munoz K; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Wei W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Wang X; Department of Epidemiology and Biostatistics, Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas.; Wang F; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Eterovic AK; Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Shaw KRM; Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Meric-Bernstam F; Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Fuller GN; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Chen K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Verhaak RG; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; The Jackson Lab for Genomic Medicine, Farmington, Connecticut.; Mills GB; Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Yung WKA; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Weathers SP; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; de Groot JF; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. zhengs3@uthscsa.edu jdegroot@mdanderson.org.

Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

Micheel CM; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Sweeney SM; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; LeNoue-Newton ML; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; André F; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Bedard PL; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Guinney J; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Meijer GA; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Rollins BJ; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Sawyers CL; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Schultz N; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Shaw KRM; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Velculescu VE; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.; Levy MA; Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101708809 Publication Model: Print Cited Medium: Internet ISSN: 2473-4276 (Electronic) Linking ISSN: 24734276 NLM ISO Abbreviation: JCO Clin Cancer Inform Subsets: MEDLINE

Korphaisarn K; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Medicine, Division of Medical Oncology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.; Loree JM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Nguyen V; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Coulson R; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Holla V; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Litzenburger BC; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Chen K; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Mills GB; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Maru DM; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Meric-Bernstan F; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Shaw KRM; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE